Severe sepsis and septic shock: Review of the literature and emergency department management guidelines

被引:317
作者
Nguyen, H. Bryant
Rivers, Emanuel P.
Abrahamian, Fredrick M.
Moran, Gregory J.
Abraham, Edward
Trzeciak, Stephen
Huang, David T.
Osborn, Tiffany
Stevens, Dennis
Talan, David A.
机构
[1] Olive View UCLA Med Ctr, Dept Emergency Med, Sylmar, CA 91342 USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
[3] Loma Linda Univ, Loma Linda, CA 92350 USA
[4] Univ Colorado, Denver, CO 80202 USA
[5] Cooper Univ Hosp, Camden, NJ 08103 USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Univ Virginia, Charlottesville, VA USA
[8] VA Med Ctr, Boise, ID USA
关键词
D O I
10.1016/j.annemergmed.2006.02.015
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Severe sepsis and septic shock are as common and lethal as other acute life-threatening conditions that emergency physicians routinely confront such as acute myocardial infarction, stroke, and trauma. Recent studies have led to a better understanding of the pathogenic mechanisms and the development of new or newly applied therapies. These therapies place early and aggressive management of severe sepsis and septic shock as integral to improving outcome. This independent review of the literature examines the recent pathogenic, diagnostic, and therapeutic advances in severe sepsis and septic shock for adults, with particular relevance to emergency practice. Recommendations are provided for therapies that have been shown to improve outcomes, including early goal-directed, early and appropriate antimicrobials, source control, recombinant human activated protein C, corticosteroids, and low tidal volume mechanical ventilation.
引用
收藏
页码:28 / 54
页数:27
相关论文
共 282 条
[1]
EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]
Abraham E, 1998, LANCET, V351, P929
[3]
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[4]
LACTATE CLEARANCE AND SURVIVAL FOLLOWING INJURY [J].
ABRAMSON, D ;
SCALEA, TM ;
HITCHCOCK, R ;
TROOSKIN, SZ ;
HENRY, SM ;
GREENSPAN, J .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1993, 35 (04) :584-589
[5]
*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801
[6]
Antibiotic synergy and antagonism [J].
Acar, JF .
MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (06) :1391-+
[7]
THE USE AND CLINICAL IMPORTANCE OF A SUBSTRATE-SPECIFIC ELECTRODE FOR RAPID-DETERMINATION OF BLOOD LACTATE CONCENTRATIONS [J].
ADUEN, J ;
BERNSTEIN, WK ;
KHASTGIR, T ;
MILLER, JA ;
KERZNER, R ;
BHATIANI, A ;
LUSTGARTEN, J ;
BASSIN, AS ;
DAVISON, L ;
CHERNOW, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (21) :1678-1685
[8]
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome [J].
Aird, WC .
BLOOD, 2003, 101 (10) :3765-3777
[9]
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[10]
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis [J].
Angus, DC ;
Laterre, PF ;
Helterbrand, J ;
Ely, EW ;
Ball, DE ;
Garg, R ;
Weissfeld, LA ;
Bernard, GR .
CRITICAL CARE MEDICINE, 2004, 32 (11) :2199-2206